Development and Evaluation of Finasteride Niosomes Targeting Hair Follicles for Androgenic Alopecia Management

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study suggests that finasteride may inhibit the enzyme PNMT, potentially contributing to its sexual and psychological side effects.

This study found that a chitosan-decorated finasteride nanosystem exhibited satisfactory drug release and retention in rat skin, suggesting it could enhance topical delivery for androgenic alopecia treatment.

In this study, microneedles combined with finasteride nanostructured lipid carriers (FIN-NLC-MNs) were found to enhance skin penetration and specifically target hair follicles, promoting hair growth and gene regulation in androgenetic alopecia.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

This review discusses the pharmacology and safety of topical finasteride for treating androgenetic alopecia and female pattern hair loss, noting positive results but reporting no new clinical findings.

This study suggests that combination therapies including minoxidil with either finasteride, low-level laser light therapy, or microneedling are more effective than minoxidil alone for treating androgenetic alopecia.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This review discusses various novel drug delivery approaches to enhance scalp drug penetration for alopecia treatment but reports no new clinical results.

In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.

This review explores the inconsistent therapeutic effects and side effects of finasteride for androgenic alopecia, highlighting the need for further research to better predict individual patient responses.

In this study, sildenafil was found to enhance human dermal papilla cell proliferation and promote hair growth in mice, suggesting potential use in alopecia treatment.

This study found that nano-transferosomal gel formulations of finasteride improved its delivery across skin layers, potentially reducing major side effects associated with oral administration for treating male pattern baldness.

This review describes the molecular interactions between androgens and Wnt/ß-catenin signaling in androgenetic alopecia but reports no new experimental or clinical findings; the authors discuss potential Wnt/ß-catenin-targeted treatments for hair growth.

In this study, researchers reviewed literature on topical delivery of finasteride for androgenetic alopecia, finding that liposomal gels with specific additives showed the highest skin permeation rates, suggesting potential for reducing systemic side effects compared to oral formulations.

This review discusses the molecular mechanisms of androgens and androgen receptors in skin disorders, particularly androgenetic alopecia, and reports no new clinical results; it highlights potential areas for future treatment development.

This study found that red ginseng oil and its major components improved hair regrowth in testosterone-treated mice by promoting an earlier anagen phase and altering related gene expressions.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This study found that polymeric nanoparticles may effectively deliver finasteride topically to hair follicles, potentially improving alopecia treatment with fewer side effects than oral forms.

This study found that using drug microplates in transdermal finasteride films enhances aqueous solubility and skin permeation compared to films with pure finasteride.

This review discusses the application of lipid nanoparticles for enhancing drug delivery through hair follicles and reports no new clinical results, emphasizing the potential role of sebum-like lipids in this context.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This study found that Puerariae Flos extract inhibited testosterone 5α-reductase and promoted hair growth in mouse models, suggesting its potential use for treating androgenic alopecia.

Ethosomes improve finasteride delivery through skin for hair loss treatment.

This research found that liquid-state liposomes and niosomes may enhance finasteride delivery to pilosebaceous units in hamsters more effectively than gel-state vesicles or hydroalcoholic solution.